Minimal/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working PartyGerrit Jan Schuurhuis, Gert J. Ossenkoppele, Robert K. Hills et al.|Blood|2018Cited by 1k
2021 Update on MRD in acute myeloid leukemia: a consensus document from the European LeukemiaNet MRD Working PartyMichael Heuser, Jacqueline Cloos, Sylvie Freeman et al.|Blood|2021Cited by 714
GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemiaAdriano Venditti, Sergio Amadori, Alfonso Piciocchi et al.|Blood|2019Cited by 215
2025 update on MRD in acute myeloid leukemia: a consensus document from the ELN-DAVID MRD Working PartyJacqueline Cloos, Michael Heuser, Peter J.M. Valk et al.|Blood|2025Cited by 22